Insider trades › Patrick J. Heron
Patrick J. Heron
A corporate insider: an officer, director or owner of more than 10% of a company. Insiders report their trades to the SEC on Form 4The form insiders use to report each purchase or sale of their company's stock. It is due within two business days of the trade. · Last filing Jun 17, 2026
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, list Patrick J. Heron's open-market buys and sells across companies in the last two years, with the Form 4 links.
Using 13F.ai, how did the stocks Patrick J. Heron bought perform after the purchase compared with the S&P 500?
Using 13F.ai, are other insiders at the same companies buying or selling at the same time as Patrick J. Heron?
Connect your AI · Plans and the 7-day free trial (card required)
Buying and selling by quarter
Dollars bought and sold on the open market over the last two years.
Bought Sold
By trade date, using the shares and price reported for each trade. Stock grants, option exercises and shares withheld for tax are left out.
Roles
The companies where this person reports as an insider, and their position at each, most recent first.
Latest open-market trades
Purchases and sales at every company, most recent filing first.
| How the stock has done since the trade date, measured against the S&P 500 over the same days. It describes the stock, not the trader's actual gain or loss. | Filing | ||||||
|---|---|---|---|---|---|---|---|
| Jan 23, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Buy | 131,425 | $68.48 | $9.0M | -9.8% | Form 4 ↗ |
| Jun 13, 2025 | ARQT Arcutis Biotherapeutics, Inc. | Buy | 2,646 | $13.08 | $34.6K | +84.1% | Form 4 ↗ |
| Jun 5, 2025 | ARQT Arcutis Biotherapeutics, Inc. | Buy | 378 | $13.41 | $5,069 | +82.0% | Form 4 ↗ |
| Jun 4, 2025 | ARQT Arcutis Biotherapeutics, Inc. | Buy | 1,890 | $13.32 | $25.2K | +86.4% | Form 4 ↗ |
| May 22, 2025 | ARQT Arcutis Biotherapeutics, Inc. | Buy | 2,520 | $13.65 | $34.4K | +77.5% | Form 4 ↗ |
| May 21, 2025 | ARQT Arcutis Biotherapeutics, Inc. | Buy | 2,520 | $13.66 | $34.4K | +76.0% | Form 4 ↗ |
| May 15, 2025 | ARQT Arcutis Biotherapeutics, Inc. | Buy | 2,520 | $13.62 | $34.3K | +79.6% | Form 4 ↗ |
| May 14, 2025 | ARQT Arcutis Biotherapeutics, Inc. | Buy | 6,300 | $13.76 | $86.7K | +79.4% | Form 4 ↗ |
| May 13, 2025 | ARQT Arcutis Biotherapeutics, Inc. | Buy | 2,374 | $13.76 | $32.7K | +75.9% | Form 4 ↗ |
| May 9, 2025 | ARQT Arcutis Biotherapeutics, Inc. | Buy | 6,300 | $13.60 | $85.7K | +75.2% | Form 4 ↗ |
| Mar 17, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Buy | 21 | $43.93 | $923 | +75.2% | Form 4 ↗ |
| Mar 14, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Buy | 528 | $44.11 | $23.3K | +78.2% | Form 4 ↗ |
| Mar 11, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Buy | 963 | $43.77 | $42.2K | +77.6% | Form 4 ↗ |
| Mar 10, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Buy | 758 | $42.66 | $32.3K | +84.0% | Form 4 ↗ |
| Mar 10, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Buy | 577 | $43.37 | $25.0K | +84.0% | Form 4 ↗ |
| Mar 7, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Buy | 580 | $43.21 | $25.1K | +85.3% | Form 4 ↗ |
| Mar 6, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Buy | 1,335 | $43.89 | $58.6K | +84.7% | Form 4 ↗ |
| Mar 5, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Buy | 267 | $44.55 | $11.9K | +81.2% | Form 4 ↗ |
| Mar 4, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Buy | 1,279 | $45.55 | $58.3K | +77.1% | Form 4 ↗ |
| Mar 4, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Buy | 56 | $45.96 | $2,574 | +77.1% | Form 4 ↗ |
Each row links to its Form 4. Since trade compares the stock’s move from the close on the trade date (or the next trading day) to its latest close with the S&P 500 over the same days, adjusted for splits and excluding dividends. It describes the stock, not what the trader made: we don’t know their purchase price, position size or later sales. A dash means the trade isn’t matched to a listed stock, or there is no closing price after it yet.
When several people report on the same filing, we list it under the first one named, so trades by someone usually listed second may be missing here. Information, not investment advice: see the disclaimer.